# Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

> **NCT04180761** · PHASE2 · WITHDRAWN · sponsor: **University Hospital Tuebingen**

## Conditions studied

- Gastric Neoplasms

## Interventions

- **DRUG:** intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)

## Key facts

- **NCT ID:** NCT04180761
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11
- **Primary completion:** 2022-03
- **Final completion:** 2022-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No partecipants Enrolled
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04180761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04180761, "Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04180761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*